EP2046728A1 - Procédé de préparation de la prégabaline et de son énantiomère opposé - Google Patents

Procédé de préparation de la prégabaline et de son énantiomère opposé

Info

Publication number
EP2046728A1
EP2046728A1 EP07766194A EP07766194A EP2046728A1 EP 2046728 A1 EP2046728 A1 EP 2046728A1 EP 07766194 A EP07766194 A EP 07766194A EP 07766194 A EP07766194 A EP 07766194A EP 2046728 A1 EP2046728 A1 EP 2046728A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
pregabalin
iii
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07766194A
Other languages
German (de)
English (en)
Inventor
Amir Avdagic
Zdenko Hamersak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Hrvatska doo
Original Assignee
Pliva Hrvatska doo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Hrvatska doo filed Critical Pliva Hrvatska doo
Publication of EP2046728A1 publication Critical patent/EP2046728A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/02—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms
    • C07C265/04—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the invention relates to the preparation of pregabalin and its opposite enantiomer, or a pharmaceutically-acceptable salt of either thereof, and to the intermediates used for their preparation.
  • Pregabalin is approved for the treatment of epilepsy, neuropathic pain and Generalised Anxiety Disorder (GAD).
  • GAD Generalised Anxiety Disorder
  • Pregabalin acts by binding to the ⁇ 2 ⁇ subunit of the voltage-dependent calcium channel in the central nervous system.
  • EP828704 describes a synthetic route for the preparation of pregabalin.
  • the synthetic route described in EP828704 includes a key step which is the classical resolution of racemic 3- (carbamoylmethy ⁇ -S-methylhexanoic acid by the use of a chiral amine in ethanol/chloroform to give (i?)-3-(carbamoylmethyl)-5-methylhexanoic acid in 35% yield (max. theoretical yield is 50%) This is followed by a Hofmann rearrangement and hydrolysis with a strong acid to give pregabalin.
  • this route provides (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) in a high enantiomeric purity, it suffers from several drawbacks that can not be avoided:
  • the present invention represents a better and more efficient method of preparing either enantiomer of 3-(aminomethyl)-5-methylhexanoic acid, but preferably the (S) enantiomer, avoiding the above mentioned problems, giving the final product in a good yield with good chemical purity and with excellent enantiomeric purity.
  • EP828704 describes that 4-isobutyl-dihydro-3H-pyran-2,6-dione is opened but, however, the racemate is formed that requires classical resolution to obtain the desired enantiomerically enriched intermediate.
  • 4-isobutyl-dihydro-3H-pyran-2,6-dione can be enantioselectively opened by enatioselective alcoholysis using a chiral amine base [preferred chiral amine bases are quinine, quinidine, hydroquinine, cinchonine, cinchonidine, epiquinidine, epicinchonidine, epicinchonine or epiquinine] and with the use of an allyl alcohol to give the desired enantiomerically enriched monoester.
  • reaction could be further improved to create further enantiomeric excess of the desired enantiomer, and improve the total yield, by lowering the reaction temperature and/or by using 0.5-1.1 mol of the chiral amine base per mol [preferably at 0.9-1.0 mol per mol or ideally at about lmol per mol] of 4-isobutyl-dihydro-3H-pyran-2,6-dione.
  • the chiral amine base after the reaction is completed, can also be easily separated and recycled (yield over 90%).
  • the product of this reaction can be then isolated as a salt with a base [preferred bases are 1 -adamantylamine, dicyclohexylamine, tert-butylamine or (S)- or (i?)- ⁇ -phenylethylamine], or optionally it can be isolated after a base/acid work-up and then selectively precipitated as a salt with the base to further improve enantiomer purity.
  • bases are 1 -adamantylamine, dicyclohexylamine, tert-butylamine or (S)- or (i?)- ⁇ -phenylethylamine
  • the salt formed has high chemical and enantiomeric purity and there is no need for further recrystallization.
  • A represents the allyl group
  • B represents the chiral amine base
  • A represents the allyl group
  • R 4 represents phenyl or C 1 -C 5 branched or straight alkyl chain, in an inert solvent and in the presence of a base, or f) ii) by activation of the carboxy group of the compound of Formula (III) and subsequent reaction with alkali metal azides or trialkylazides to obtain acid azides, which are then converted to the corresponding rearranged isocyanates,
  • A represents the allyl group
  • A' is an allyl group that may be the same or different from A ;
  • the final product of the reaction may be recrystallised from an inert solvent in order to improve the purity of the product or to change the solid state characteristics of the product, such as morphology or physical form.
  • intermediates (VI) and (VII) are not isolated during the reaction.
  • intermediate (IV) is isolated during the reaction.
  • step b) and/ or step g) the allyl alcohol is one of Formula (E)
  • each Ri, R 2 and R 3 can be identical or different and are selected from H, Ci-C 5 branched or straight alkyl chain, phenyl [optionally substituted by halogen, cyano, trifluoromethoxy, nitro, trifluoromethyl or by Ci-C 5 branched or straight alkyl chain], or R 2 may also represents a 5- to 7- membered aromatic heterocyclic group.
  • Preferred 5- to 7-membered aromatic heterocyclic groups are selected from, pyridyl, thienyl, furyl, oxazolyl or imidazolyl.
  • Preferred allyl alcohols of Formula (E) are cinnamyl alcohol, allyl alcohol, crotyl alcohol, 3- penten-2-ol, 2-methyl-2-propen-l-ol, l,5-hexadien-3-ol, 2-hexen-l-ol, 2-methyl-3-phenyl-2- propen-1-ol, 2-hexen-l-ol, 2-penten-l-ol, 4-nitrocinnamyl alcohol, 3-buten-2-ol, l-hexen-3-ol, 1- octen-3-ol or l-penten-3-ol.
  • preferred chiral amine bases for enantioselective alcoholysis are cinchona alkaloids, especially: quinine, quinidine, hydroquinine, cinchonine, cinchonidine, epiquinidine, epicinchonidine, epicinchonine or epiquinine.
  • the chiral amine is added in 0.5-1.1 mol per mol of Formula (I) [ideally at 0.9-1.0 mol per mol, ideally about 1 mol per mol] and/or is preferably present as an enantiomerically pure form.
  • the process is performed in an inert solvent selected from toluene, xylene, tetrahydrofuran, dioxane, methylene chloride, acetonitrile, dimethylformamide, diisopropyl ether or methyl tert-butyl ether, or a mixture of any thereof.
  • an inert solvent selected from toluene, xylene, tetrahydrofuran, dioxane, methylene chloride, acetonitrile, dimethylformamide, diisopropyl ether or methyl tert-butyl ether, or a mixture of any thereof.
  • the reaction is conducted at a temperature from -70 to 3O 0 C.
  • preferred bases D for precipitation of compound of Formula (III), are 1 - adamantylamine, dicyclohexylamine, tert-butylamine, (S)- or ( ⁇ )- ⁇ -phenylethylamine.
  • the compounds of Formula (III) may first be reacted with a simple base, such as potassium carbonate, sodium carbonate or sodium-hydrogen carbonate, then by washing of the water layer containing the salt compound of Formula (III) with an organic solvent, liberating the compound of Formula (III) by dilute acid.
  • the compound of formula (III) can then be reacted with a base D as described above
  • step f) compounds of Formula (VII) are obtained from compounds of Formula (III) via a Curtius rearrangement, see for Curtius rearrangement ,for example, E.F. Scriven, K. Turnbull, Chem. Rev., 1988, 88, 297.
  • Suitable azides of Formula (V) for the Curtius rearrangement are phosphoric acid ester-azide, such as phosphoric acid diphenyl ester-azide or phosphoric acid diethyl ester-azide.
  • Curtius rearrangement is in general carried out in suitable inert solvents such as toluene, benzene, xylene, dioxane or tetrahydrofuran.
  • Suitable bases for Curtius rearrangement are organic amines selected from N-ethylmorpholine, N-methylmorpholine, pyridine or triethylamine preferably in an amount of lmol to 3mol per mol of compounds of Formula (III). Also, it is possible first to convert carboxylic acid to corresponding derivatives by activating reagents, such as C 1 -C 4 alkyl chloroformates in presence of amine, thionyl chloride or phosphorus pentachloride and then prepare carboxylic acid azides by reaction with alkali metal azides or trialkylsilyl azide.
  • reagents such as C 1 -C 4 alkyl chloroformates
  • the acid azides can be transformed to corresponding isocyanates, which can be optionally isolated and reacted with an allyl alcohol, preferably of Formula (E), to give compounds of Formula (VII).
  • an allyl alcohol preferably of Formula (E)
  • the Curtius rearrangement reaction is conducted at a temperature of from 20 to HO 0 C.
  • step h) the splitting off of urethane and ester function of the compounds of Formula (VII) is conducted with a catalytic amount of palladium catalyst and/or a phosphine and a nucleophilic auxiliary in an inert solvent.
  • the inert solvent in this reaction is selected from ethanol, tetrahydrofuran, 2-propanol, n-propanol or dioxane, or a mixture of any thereof.
  • the reaction is conducted at a temperature of from 10 to 9O 0 C.
  • Suitable nucleophilic auxiliaries for the splitting off of urethane and ester function are selected from triethylamine, dimedone, tributyltin hydride, ammonium formate, morpholine or pyrrolidine, preferably in an amount of 1 mol to 4 mol per mol of compounds of Formula (VII).
  • Suitable palladium catalysts are selected from, Pd(PPh 3 ) 4 , Pd(OAc) 2 , PdCl 2 , Pd(dba) 2 or (Pd 2 (dba) 3 ), preferably in an amount of 0.0005 mol to 0.2 mol per mol of compounds of Formula (VII).
  • Suitable phosphines are selected from, triphenylphosphine, triisopropylphosphine or tri-o- tolylphosphine, preferably in an amount of 0.002 mol to 0.8 mol per mol of compounds of Formula (VII).
  • enantiomerically enriched we mean that the enantiomeric excess (ee) is greater than 60%, greater than 65% or greater than 70%.
  • enantiomerically pure we mean that the enantiomeric excess (ee) is greater than 90%, ideally greater than 99% and ideally enantiomerically pure means greater than 99.5%.
  • Diacid 50 g, 266 mmol was placed in propionic anhydride (130 ml) and the reaction mixture was heated at 140-145 °C during 6 hours.
  • Propionic acid and propionic anhydride were distilled in vacuo (30-60 °C/15 mm Hg).
  • Product was collected at 100-105 °C/0.5 mm Hg as yellowish oil. Yield 41 g (91 %), GC purity: >98% (HP-I, 25 m, 70 kPa, gradient 70-240 0 C, 15 °C/min).
  • reaction mixture was washed with a solution of 1 g NaNO 2 and 1,5. g NaHCO 3 in H 2 O (10OmL), than with H 2 O (10OmL) and evaporated under reduced pressure to yield 25.8g of crude oily (S)- Cinnamyl 3-((cinnamyloxycarbonylamino)methyl)-5-methylhexanoate which was used without further purification in the next step.

Abstract

L'invention concerne la préparation de la prégabaline et de son énantiomère opposé, ou d'un sel pharmaceutiquement acceptable de n'importe lequel de ces composés, et les composés intermédiaires utilisés dans leur préparation.
EP07766194A 2006-07-15 2007-07-11 Procédé de préparation de la prégabaline et de son énantiomère opposé Withdrawn EP2046728A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0614133A GB0614133D0 (en) 2006-07-15 2006-07-15 Process for preparing a pharmaceutical compound
PCT/GB2007/002607 WO2008009897A1 (fr) 2006-07-15 2007-07-11 Procédé de préparation de la prégabaline et de son énantiomère opposé

Publications (1)

Publication Number Publication Date
EP2046728A1 true EP2046728A1 (fr) 2009-04-15

Family

ID=36955756

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07766194A Withdrawn EP2046728A1 (fr) 2006-07-15 2007-07-11 Procédé de préparation de la prégabaline et de son énantiomère opposé

Country Status (4)

Country Link
EP (1) EP2046728A1 (fr)
EA (1) EA200970126A1 (fr)
GB (1) GB0614133D0 (fr)
WO (1) WO2008009897A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160281A (zh) 2005-04-06 2008-04-09 特瓦制药工业有限公司 结晶形态的普瑞巴林
US7488846B2 (en) 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
KR100893312B1 (ko) 2005-05-10 2009-04-15 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린 및 이의 염의 제조 방법
CA2604600A1 (fr) 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabaline exempte d'acide isobutylglutarique et son procede de preparation
CA2604624A1 (fr) 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Resolution optique de l'acide 3-carbamoylmethyl-5-methyl hexanoique
KR20070087596A (ko) 2005-09-19 2007-08-28 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-(+)-3-(아미노메틸)-5-메틸헥산산의 비대칭 합성
KR20080027880A (ko) 2006-05-24 2008-03-28 테바 파마슈티컬 인더스트리즈 리미티드 Ｒ-(+)-3-(카바모일메틸)-5-메틸헥산산 및 이의 염의 제조방법
BRPI0803092A2 (pt) 2007-03-22 2011-08-30 Teva Pharma sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina
CN101333165B (zh) * 2008-08-05 2011-05-04 浙江大学 一种戊二酸单甲酯的合成方法
IT1394292B1 (it) * 2009-05-07 2012-06-06 Dipharma Francis Srl Procedimento per la sintesi di pregabalina
WO2012059797A1 (fr) * 2010-11-04 2012-05-10 Lupin Limited Procédé de synthèse de la (s)-prégabaline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008009897A1 *

Also Published As

Publication number Publication date
EA200970126A1 (ru) 2009-06-30
WO2008009897A1 (fr) 2008-01-24
GB0614133D0 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
EP2046728A1 (fr) Procédé de préparation de la prégabaline et de son énantiomère opposé
EP0830338B1 (fr) Procédé de preparation de l'acide 3-(aminométhyl)-5-méthylhexanoique
EP1250311B1 (fr) Synthese asymetrique de pregabaline
EP0828704B1 (fr) Procedes de production d'acide (s)-3-(aminomethyl)-5-methylhexanoique
WO2008062460A2 (fr) Formes cristallines de la prégabaline
WO2014068333A2 (fr) Nouveau procédé
JP2002508345A (ja) 不斉水素化
EP2050738B1 (fr) Nouveau dérivé d'imidazolidinone, procédé de production de ce dérivé et procédé de production d'un acide aminé optiquement actif
EP1489066B1 (fr) Procede de production d'acide carboxylique optiquement actif
AU700091C (en) Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
JPH1059947A (ja) キラルで、非ラセミの（４−アリール−２，５−ジオキソイミダゾリジン−１−イル）酢酸の製造方法
KR20110086167A (ko) γ-아미노-α,β-불포화 카르복실산 유도체의 거울상이성질체선택적 합성
KR20090026794A (ko) 광학활성을 갖는 암로디핀의 제조방법
WO2014012832A1 (fr) Procédé pour la préparation de 2-(3-n,n-diisopropylamino-1-phénylpropyl)-4-hydroxyméthylphénol et de ses dérivés

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20090119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202